tegafur has been researched along with Ascites in 32 studies
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.22 | Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "We used combination therapy of S-1 and Paclitaxel to treat gastric cancer complicated by carcinomatous ascites and assessed the clinical results." | 7.74 | [Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2007) |
| "We report a case in which TS-1 + paclitaxel (PTX) administration was effective for gastric cancer with malignant ascites." | 7.73 | [Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K, 2005) |
| "Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 7.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
| "Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 5.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
| "Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 5.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
| "We report two cases of advanced gastric cancer." | 5.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
| " Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 5.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "A 38-year-old female patient with gastric cancer, of which histological type was a poorly differenciated adenocarcinoma and a clinical finding was T3N1MO (Stage IIIA), underwent total gastrectomy with D2 lymphadenectomy as the surgical treatment." | 5.33 | [A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer]. ( Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006) |
| "Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.22 | Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "We used combination therapy of S-1 and Paclitaxel to treat gastric cancer complicated by carcinomatous ascites and assessed the clinical results." | 3.74 | [Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2007) |
| "We report a case in which TS-1 + paclitaxel (PTX) administration was effective for gastric cancer with malignant ascites." | 3.73 | [Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K, 2005) |
| "Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 3.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
| "We treated a patient with inoperable advanced gastric cancer and malignant ascites by combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)." | 3.72 | [A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)]. ( Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T, 2003) |
| " The mean values of 5-fluorouracil (5-FU) concentrations in ascites of the S-1 group at 1-4 h were 414-580 ng/ml (n=5), and those of FT group were 70-87 ng/ml (n=5), with significant differences between the two groups at each observation time." | 3.72 | Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. ( Hirakawa, K; Nakata, B; Yamagata, S, 2004) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1." | 1.46 | Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. ( Fujiya, M; Hasebe, T; Honda, S; Nakajima, S; Okumura, T; Sawada, K, 2017) |
| "Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 1.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
| "Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 1.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
| "We report two cases of advanced gastric cancer." | 1.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
| "We report two cases of advanced gastric cancer successfully treated with combination S-1 and docetaxel (DOC) therapy." | 1.36 | [Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel]. ( Hasegawa, H; Kijima, T; Kitahara, M; Kubo, H; Miyahara, M; Tada, K, 2010) |
| " Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 1.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "A 38-year-old female patient with gastric cancer, of which histological type was a poorly differenciated adenocarcinoma and a clinical finding was T3N1MO (Stage IIIA), underwent total gastrectomy with D2 lymphadenectomy as the surgical treatment." | 1.33 | [A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer]. ( Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006) |
| "Treatment of advanced gastric cancers with peritonitis carcinomatosa is very difficult, because none of the various therapies (operation, chemotherapy, hyperthermia etc." | 1.32 | [A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites]. ( Doi, K; Horiuchi, T; Nakamura, T; Okubo, Y; Shimada, K; Tanabe, S; Tanaka, K; Tanaka, S; Uchinami, M; Yoshida, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, S | 1 |
| Sawada, K | 1 |
| Hasebe, T | 1 |
| Nakajima, S | 1 |
| Fujiya, M | 1 |
| Okumura, T | 1 |
| Arai, H | 1 |
| Iwasa, S | 1 |
| Boku, N | 1 |
| Kawahira, M | 1 |
| Yasui, H | 1 |
| Masuishi, T | 1 |
| Muro, K | 2 |
| Minashi, K | 1 |
| Hironaka, S | 1 |
| Fukuda, N | 1 |
| Takahari, D | 2 |
| Nakajima, TE | 1 |
| Kitayama, J | 5 |
| Ishigami, H | 5 |
| Yamaguchi, H | 4 |
| Yamashita, H | 3 |
| Emoto, S | 2 |
| Kaisaki, S | 2 |
| Watanabe, T | 4 |
| Takahara, N | 2 |
| Isayama, H | 2 |
| Nakai, Y | 2 |
| Sasaki, T | 2 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Mizuno, S | 2 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 2 |
| Yamamoto, N | 2 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 2 |
| Koike, K | 2 |
| Iwai, N | 1 |
| Wakabayashi, N | 1 |
| Matsumoto, N | 1 |
| Morita, Y | 1 |
| Tanaka, N | 1 |
| Yoriki, H | 1 |
| Fujii, K | 1 |
| Takada, R | 1 |
| Takaya, H | 1 |
| Masuzawa, A | 1 |
| Takami, S | 1 |
| Kataoka, K | 1 |
| Ito, T | 1 |
| Hanafusa, N | 1 |
| Shinoto, M | 1 |
| Nakamura, K | 1 |
| Shioyama, Y | 1 |
| Nishie, A | 1 |
| Asayama, Y | 1 |
| Ohga, S | 1 |
| Yoshitake, T | 1 |
| Terashima, K | 1 |
| Asai, K | 1 |
| Matsumoto, K | 1 |
| Honda, H | 1 |
| Satoi, S | 2 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Ohe, C | 1 |
| Miyasaka, C | 1 |
| Uemura, Y | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Ryota, H | 1 |
| Michiura, T | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Tanigawa, N | 1 |
| Kon, M | 1 |
| Matsubara, S | 1 |
| Kubo, H | 1 |
| Kijima, T | 1 |
| Kitahara, M | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Hasegawa, H | 1 |
| Hidemura, A | 1 |
| Kato, M | 1 |
| Otani, K | 1 |
| Kamei, T | 1 |
| Soma, D | 1 |
| Miyato, H | 1 |
| Nagawa, H | 1 |
| Ohdaira, H | 1 |
| Suzuki, Y | 1 |
| Tsutsui, M | 1 |
| Iwasaki, T | 1 |
| Arita, M | 1 |
| Noro, T | 1 |
| Kawasaki, N | 1 |
| Ohara, T | 1 |
| Yoshino, K | 1 |
| Kuroda, H | 1 |
| Kitajima, M | 3 |
| Shitara, K | 1 |
| Mizota, A | 1 |
| Matsuo, K | 1 |
| Sato, Y | 1 |
| Kondo, C | 1 |
| Ura, T | 1 |
| Tajika, M | 1 |
| Okumura, K | 1 |
| Tani, S | 1 |
| Shiogai, Y | 1 |
| Kodama, M | 1 |
| Mekata, E | 1 |
| Tan, T | 1 |
| Ohno, T | 1 |
| Horiguchi, N | 1 |
| Asukai, K | 1 |
| Miura, A | 1 |
| Koguchi, H | 1 |
| Shimizu, S | 1 |
| Matsunaga, S | 1 |
| Togawa, S | 1 |
| Hasegawa, I | 1 |
| Sakakibara, K | 1 |
| Iwakura, S | 1 |
| Shimamoto, T | 1 |
| Higashiguchi, T | 1 |
| Nakase, T | 1 |
| Shimada, K | 2 |
| Kunimoto, H | 1 |
| Aoki, Y | 1 |
| Nakanishi, H | 1 |
| Mochizuki, Y | 1 |
| Kodera, Y | 1 |
| Ito, S | 1 |
| Yamamura, Y | 1 |
| Ito, K | 1 |
| Akiyama, S | 1 |
| Nakao, A | 1 |
| Tatematsu, M | 1 |
| Hatanaka, F | 1 |
| Matsuo, S | 1 |
| Aratake, Y | 1 |
| Uchimura, K | 1 |
| Yokota, M | 1 |
| Sumii, T | 1 |
| Iguchi, H | 1 |
| Funakoshi, A | 1 |
| Tanaka, A | 1 |
| Funai, S | 1 |
| Ohtsuka, H | 1 |
| Yoshifuji, T | 1 |
| Hirai, T | 1 |
| Shindo, K | 1 |
| Shiozaki, H | 1 |
| Kamei, A | 1 |
| Akatsu, Y | 2 |
| Saikawa, Y | 2 |
| Kubota, T | 2 |
| Yoshida, M | 3 |
| Furukawa, T | 1 |
| Otani, Y | 2 |
| Kumai, K | 2 |
| Nakamura, T | 2 |
| Okubo, Y | 1 |
| Tanaka, S | 1 |
| Tanabe, S | 1 |
| Doi, K | 1 |
| Uchinami, M | 1 |
| Horiuchi, T | 1 |
| Tanaka, K | 1 |
| Yamagata, S | 1 |
| Nakata, B | 1 |
| Hirakawa, K | 1 |
| Shibata, N | 1 |
| Eto, TA | 1 |
| Hotokezaka, M | 1 |
| Iwamura, T | 1 |
| Chijiiwa, K | 1 |
| Nakamura, R | 1 |
| Takahashi, T | 1 |
| Sugihara, S | 1 |
| Ikuta, Y | 1 |
| Kobayashi, H | 1 |
| Tsuruta, Y | 1 |
| Yonemitsu, K | 1 |
| Toyama, E | 1 |
| Teshima, K | 1 |
| Toshimitsu, H | 1 |
| Matoba, K | 1 |
| Ozasa, H | 1 |
| Shimizu, R | 1 |
| Hara, A | 2 |
| Tsunemi, S | 2 |
| Yamamoto, M | 2 |
| Izumi, N | 2 |
| Iwamoto, S | 2 |
| Imamura, H | 1 |
| Furukawa, H | 1 |
| Kishimoto, T | 1 |
| Miyazaki, Y | 1 |
| Yamamoto, K | 1 |
| Ohshiro, R | 1 |
| Ohta, K | 1 |
| Nakata, Y | 1 |
| Kamigaki, S | 1 |
| Kondo, M | 1 |
| Takemoto, H | 1 |
| Fujimi, S | 1 |
| Nakayama, T | 1 |
| Fukunaga, M | 1 |
| Ohsato, H | 1 |
| Tatsuta, M | 1 |
| Ohtani, S | 1 |
| Shimizu, Y | 1 |
| Sugiyama, S | 1 |
| Miyade, Y | 1 |
| Ninomiya, M | 1 |
| Okada, S | 1 |
| Okazaki, N | 1 |
| Nose, H | 1 |
| Yoshimori, M | 1 |
| Aoki, K | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Arase, Y | 1 |
| Chayama, K | 1 |
| Gunji, T | 1 |
| Yoshiba, A | 1 |
| Irimoto, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study[NCT04886193] | 20 participants (Anticipated) | Interventional | 2021-04-16 | Recruiting | |||
| The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for tegafur and Ascites
| Article | Year |
|---|---|
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineopl | 2016 |
30 other studies available for tegafur and Ascites
| Article | Year |
|---|---|
Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Carcinoma, Hepatocellular; Di | 2017 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectom | 2015 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; | 2015 |
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuv | 2017 |
[Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Adm | 2010 |
Laparoscopy-assisted total gastrectomy for advanced gastric cancer with carcinomatous ascites after S1 plus cisplatin chemotherapy: a case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); D | 2012 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; D | 2012 |
[A case of gastric cancer with peritoneal dissemination and massive ascites successfully treated with S-1/docetaxel therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Docetaxel; Drug Combinations; Femal | 2012 |
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma; Cell Count; Dose | 2003 |
[A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combina | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin.
Topics: Ascites; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Drug Therapy, Combination; Femal | 2004 |
[A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Drug Administrati | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
[An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2005 |
[Preoperative combination chemotherapy with TS-1 is effective in a case gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Drug Administrat | 2005 |
[Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined M | 2005 |
[A resected case of effective treatment with TS-1 and CDDP for advanced gastric cancer with carcinomatous ascites].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cholecystectomy; Cisplatin; Combined | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Comb | 2006 |
[A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
[Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Adm | 2007 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa | 1992 |
[Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Diseases; Carcinoma, Hepatocell | 1988 |